Tagrisso (osimertinib) | Patient support

This website is only intended for UK patients who have been prescribed TAGRISSO^® (osimertinib), which is indicated after surgery in adults with stage 1B-3A NSCLC with a particular EGFR mutation, and also in locally advanced or metastatic NSCLC with a particular EGFR mutation. It does not replace the Patient Information Leaflet, which you can find in the carton containing your medicine and which you should read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.

Reporting side effects

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme, website: https://yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of medicines.

Side effects can also be reported to AstraZeneca in the following ways:

Online: https://contactazmedical.astrazeneca.com

Email: Medical.InformationUK@astrazeneca.com

No imagery of real patients has been used on this site.

Supporting you throughout your osimertinib lung cancer treatment

Your journey to learning more about your treatment

What would you like to learn about today?

Welcome to tagrissoandme.co.uk*

Supporting you throughout your osimertinib lung cancer treatment

Your journey to learning more about your treatment

What would you like to learn about today?